Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 29, 2024 10:04pm
317 Views
Post# 36063587

Buy out talk. Time…

Buy out talk. Time…Clearly Roche is a prime candidate to buyout oncolytics biotech.
They have been in Gobblet with both feet.
Now with a new expanded cohurt....yet another phase 3 opportunity.
Being MBc ( Roche not much interst) , pancreatic cancer ( co- therapy  with Roche & possibly of being a blockbuster tretment), most recent anal cancer co therapy , again with Roche.
They do still have in the background CAR-T applications & trials.
Also a tripple neg trial with Incyte, 
one thing they have done is later focused on the most favourable outcomes & quickest route to market.
again back to Gobblet & Roche.
pfizer is still in the game awaiting the O.S. Results from the Aware- 1 trial.
i do not know enough about the potential sales of the panc or anal.
however it was sumized quite a while ago, thst MBc alone is a $5 billion/ year market.
back to my timlines a few days ago.
this quarter, we are told to expect 3-4 updates.
In importance being whar the FDA has to say regarding MBc.
followed by the CGAR trial details.
Even low balling, one of the 3 makes Onc a $ billion company.
that being before phase 3 is mid way.
I'd say, with some good news out of FDA & CGAR updates , a biuyout would make sense.
let Roche carry the ball across the finish line.
My guess ( assuming the mentioned updates)3  $billion to $5 billion.
noteable has given ample examples iof buyouts  for much more, with pharmas offering much less.
The day traders, shorters & A.I. Followers , getting all excited over a few dimes, regrettably have no idea of the potential.
yup, each billion represents about $12usd/ share.
save the low SP argument.
look up investopedia , under micro pharma evaluations,
pall to do with future potential outcomes frrom the product, for the aquiring company.
many layers to that question.
including new patents in co- theraoy treatments.
Anyhow end of June is " this quarter"...
news ?
FDA first, then CGAR, then either a partneship or buyout.
im not promising, for those who like to miss quote me & take out if context.
im saying, that is possible & that fast.
All the negotiations coukd be in progress, pending solid FDA outcomes.









<< Previous
Bullboard Posts
Next >>